SCHEMBL29965175

SCHEMBL29965175

Cc1c2cc(C(=O)N3C[C@@H]4CC[C@@H](Nc5ccc(Br)nn5)[C@@H]4C3)sc2nn1C

nearest known ligand 0.32

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.32
MGLL Q99685 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TSHR P16473 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29965145 0.88 MGLL (0.42) MGLLMEN1KMT2ATSHRNPSR1
SCHEMBL29965105 0.87
SCHEMBL29964844 0.83
SCHEMBL26983404 0.81 ALDH1A1 (0.40)
SCHEMBL26983410 0.81 SLC6A9 (0.31)
SCHEMBL29964627 0.81
SCHEMBL26983456 0.80 ALDH1A1 (0.34) KMT2AL3MBTL1
SCHEMBL29964883 0.79 GPR183 (0.31)
SCHEMBL29964836 0.78 MARK3 (0.38)
SCHEMBL26983425 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2026-04-14 US disclosed
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US disclosed
EP-4317153-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2024-02-07 EP disclosed
US-20240010658-A1 ABHD6 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2024-01-11 US disclosed
WO-2022211060-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240010658-A1 ABHD6 ANTAGONIST ABHD6, ABHD16A, ABHD12 KDR 4710/4885MGLL 3333/4885MEN1 3300/4885
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ABHD6, ABHD16A, PITHD1 KDR 4750/4885MGLL 3957/4885MEN1 4379/4885
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, HDHD5 KDR 4713/4885MGLL 2445/4885MEN1 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.